| Publications | PubMed=2544546; DOI=10.1007/BF02623562
Miyagiwa M., Ichida T., Tokiwa T., Sato J., Sasaki H.
A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium.
In Vitro Cell. Dev. Biol. 25:503-510(1989) DOI=10.11418/jtca1981.16.3_173
Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-i., Ohashi R., Namba M.
The p53 gene status and other cellular characteristics of human cell lines maintained in our laboratory.
Tissue Cult. Res. Commun. 16:173-178(1997) PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997) PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010) PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010) PubMed=21451941; DOI=10.1007/s00534-011-0376-7
Sato J., Kimura T., Saito T., Anazawa T., Kenjo A., Sato Y., Tsuchiya T., Gotoh M.
Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
J. Hepatobiliary Pancreat. Sci. 18:700-711(2011) PubMed=21687941; DOI=10.3892/ijo.2011.1087
Kamigaki M., Sasaki T., Serikawa M., Inoue M., Kobayashi K., Itsuki H., Minami T., Yukutake M., Okazaki A., Ishigaki T., Ishii Y., Kosaka K., Chayama K.
Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells.
Int. J. Oncol. 39:561-568(2011) PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012) CLPUB00275
Zach S., Birgin E., Ruckert F.
Primary cholangiocellular carcinoma cell lines.
J. Stem Cell Res. Transplant. 2:1013-1013(2015) PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015) PubMed=26956050; DOI=10.18632/oncotarget.7914; PMCID=PMC4991440
Ding X.-W., Chaiteerakij R., Moser C.D., Shaleh H.M., Boakye J., Chen G., Ndzengue A., Li Y., Zhou Y.-L., Huang S.-B., Sinicrope F.A., Zou X.-P., Thomas M.B., Smith C.D., Roberts L.R.
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Oncotarget 7:20080-20092(2016) PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442; PMCID=PMC5458737
Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C., Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K., Greninger P., McDermott U., Garnett M.J., Jenkins R.L., Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y., Goyal L., Ferrone C.R., Zhu A.X.-X., Joung J.K., Shokat K.M., Benes C.H., El-Bardeesy N.
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma.
Cancer Discov. 6:727-739(2016) PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016) PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019) PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019) PubMed=31077409; DOI=10.1002/hep.30704
Sittithumcharee G., Suppramote O., Vaeteewoottacharn K., Sirisuksakun C., Jamnongsong S., Laphanuwat P., Suntiparpluacha M., Matha A., Chusorn P., Buraphat P., Kakanaporn C., Charngkaew K., Silsirivanit A., Korphaisarn K., Limsrichamrern S., Tripatara P., Pairojkul C., Wongkham S., Sampattavanich S., Okada S., Jirawatnotai S.
Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity.
Hepatology 70:1614-1630(2019) PubMed=31395879; DOI=10.1038/s41467-019-11415-2; PMCID=PMC6687785
Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
Nat. Commun. 10:3574.1-3574.11(2019) PubMed=32899426; DOI=10.3390/cancers12092510; PMCID=PMC7565451
Scherer D., Davila-Lopez M., Goeppert B., Abrahamsson S., Gonzalez Silos R., Nova I., Marcelain K., Roa J.C., Ibberson D., Umu S.U., Rounge T.B., Roessler S., Lorenzo-Bermejo J.
RNA sequencing of hepatobiliary cancer cell lines: data and applications to mutational and transcriptomic profiling.
Cancers (Basel) 12:2510.1-2510.14(2020) PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007; PMCID=PMC9472155
Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y., Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S., Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.
Development and characterization of human primary cholangiocarcinoma cell lines.
Am. J. Pathol. 192:1200-1217(2022) PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022) |
|---|
